Medical Digest & Congress Report
Episodes
What is New : Osteoporosis in Rheumatology - report from EULAR2024
21 Jun 2024
Contributed by Lukas
Professor Willem Lems share his thoughts on the latest developments in the diagnosis and therapy of osteoporosis as it pertains to the RMDs. Video: ht...
Interstitial Lung Disease: from diagnosis to management - report from EULAR2024
21 Jun 2024
Contributed by Lukas
Professor Anna-Maria Hoffmann-Vold gave us a review of the most recent data from the diagnosis to the management of interstitial lung disease in RMDs....
Promising directions in the treatment of Psoriatic Arthritis - report from EULAR2024
21 Jun 2024
Contributed by Lukas
Professor Rik Lories on the current challenges in prevention and treatment of psoriatic arthritis. Video: https://medicaldigest.org/scientific-conten...
Update of EULAR recommendations for the treatment of Systemic Sclerosis - report from EULAR2024
21 Jun 2024
Contributed by Lukas
Professor Francesco Del Galdo share his thoughts about EULAR Recommendations for the treatment of Systemic Sclerosis. Video: https://medicaldigest.org...
Lupus: what's on the horizon? - report from EULAR2024
20 Jun 2024
Contributed by Lukas
Professor David Isenberg shares an update on novel treatments for lupus and their clinical applications. Video: https://medicaldigest.org/scientific-...
Secukinumab versus standard-of-care in axial spondyloarthritis - report from EULAR2024
20 Jun 2024
Contributed by Lukas
Professor Denis Poddubnyy shared the results of AScalate trial, Secukinumab versus standard-of-care in axial spondyloarthritis, a randomized controlle...
Difficult Questions in Osteoporosis - report from EULAR2024
20 Jun 2024
Contributed by Lukas
Professor Roland Chapurlat shares his experiences on high risk osteoporosis combination terapies, on OP and CKD, as well on pregnancy and OP. Video: h...
Update on EULAR/ACR Project: Risk Stratification in patients with arthralgia suspicious for progression to RA - report from EULAR2024
20 Jun 2024
Contributed by Lukas
Professor Annette H. M. van der Helm van Mil share her thoughts about EULAR Recommendations on risk stratification in patients with arthralgia suspici...
Cardiovascular Comorbidities of Rheumatic and Musculoskeletal Diseases - report from EULAR2024
20 Jun 2024
Contributed by Lukas
Professor Anja Strangfeld chaired an important session during EULAR 2024 on cardiovascular comorbidities of Rheumatic and Musculoskeletal Diseases and...
Fatigue, Pain and Opioids in Rheumatological Diseases - report from EULAR2024
20 Jun 2024
Contributed by Lukas
Professor Rene Westhovens chaired an interesting session during EULAR 2024, where participants learned to recognise the range of pain and fatigue mani...
Asymptomatic ultrasonographic urate deposition in the joint - are there long-term consequences? - report from EULAR2024
19 Jun 2024
Contributed by Lukas
Professor Mariano Andrés on the long-term consequences of asymptomatic urate deposition in the joint. Video: https://medicaldigest.org/scientific-con...
Cardiovascular Risk in Rheumatic & Musculoskeletal Disease - report from EULAR2024
19 Jun 2024
Contributed by Lukas
Professor Michael Nurmohamed shares his experiences on cardiovascular comorbidities of Rheumatic and Musculoskeletal Diseases and their management, as...
"Asymptomatic" Hyperuricemia: Innocent bystander or menacing foe? - report from EULAR2024
19 Jun 2024
Contributed by Lukas
Professor Francisca Sivera chaired an informative session during EULAR 2024, on the long-term consequences of asymptomatic urate deposition in the joi...
Rheumatoid Arthritis Prevention: what have we learnt, and where do we go next? - report from EULAR2024
19 Jun 2024
Contributed by Lukas
Professor Raphael Micheroli chaired an exciting session during EULAR 2024, an update on the results of RA prevention trials to date, describe the less...
Metabolic Reprogramming in Autoimmunity - report from EULAR2024
19 Jun 2024
Contributed by Lukas
Professor Valentina Pucino chaired an interesting session during EULAR 2024 on critical metabolic pathways and the interplay between metabolism and im...
Overview of the 2024 EAS Congress
19 Jun 2024
Contributed by Lukas
We asked Professor Kausik Ray, President of the European Atherosclerosis Society about 2024 EAS Congress and the Society, as well as the Joint Session...
Combination of a beta-blocker with calcium channel blocker in hypertension - report from ESH2024
12 Jun 2024
Contributed by Lukas
Professor Gianfranco Parati share his thoughts on combination of a beta-blocker with calcium channel blocker in hypertension. Video: https://medicaldi...
2023 ESH Hypertension Guideline Update - report from ESH2024
12 Jun 2024
Contributed by Lukas
Professor Rosa de Pinho on 2023 ESH Hypertension Guideline Update. Video: https://medicaldigest.org/scientific-contents/interview:2023-esh-hypertensio...
ESH - ESC HFA Joint meeting: HFpEF update 2024 - report from ESH2024
12 Jun 2024
Contributed by Lukas
Professor Enrico Agabiti Rosei on heart failure with preserved ejection fraction updates at ESH 2024. Video: https://medicaldigest.org/scientific-cont...
ESH guidelines 2023: a new light on beta-blockers in hypertension - report from ESH2024
12 Jun 2024
Contributed by Lukas
Professor Giuseppe Mancia on the update of ESH guidelines 2023. Video: https://medicaldigest.org/scientific-contents/interview:esh-guidelines-2023-new...
Management of older hypertensive patients - report from ESH2024
12 Jun 2024
Contributed by Lukas
Professor Athanase Benetos on how to take care and treat hypertensive older people. Video: https://medicaldigest.org/scientific-contents/interview:man...
Controlling the uncontrollable - resistant hypertension and the role of aldosterone - report from ESH2024
12 Jun 2024
Contributed by Lukas
Professor Michel Azizi on aldosterone receptor blocker versus aldosterone synthase inhibitor. Who is more effective in blocking aldosterone? Video: ht...
How lifestyle affects hypertension - report from ESH2024
11 Jun 2024
Contributed by Lukas
Professor Fadi Charchar on how lifestyle affects hypertension and what a patient could do to prevent hypertension and reduce then blood pressure. Vide...
ESH - ISH Joint Session: Balancing common side effects of Thiazide/Thiazide-like diuretics through addition of other Blood Pressure lowering drugs - report from ESH2024
11 Jun 2024
Contributed by Lukas
Professor Jorie Versmissen and Professor Fadi Charchar discussed the ESH - ISH Joint Session on balancing common side effects of Thiazide/Thiazide-lik...
Beta-blockers in hypertension and CVD - report from ESH2024
11 Jun 2024
Contributed by Lukas
Professor Ricardo Fontes-Carvalho on the role of beta-blockers in the treatment of hypertension and cardiologic diseases. Video: https://medicaldigest...
Diabetes and Metabolic risk factors - report from ESH2024
11 Jun 2024
Contributed by Lukas
Professor Josep Redon chaired an interesting session on Diabetes and Metabolic risk factors at ESH 2024. Video: https://medicaldigest.org/scientific-c...
Nephroprotection using SGLT2 inhibitors in patients with hypertension - report from ESH2024
11 Jun 2024
Contributed by Lukas
Professor Michael Böhm on evolving standard of care and SGLT2 inhibitors for patients with CKD and hypertension. Video: https://medicaldigest.org/sci...
ESH Clinical Practice Guidelines - report from ESH2024
11 Jun 2024
Contributed by Lukas
Professor Roland Schmieder, Co-Chair of ESH 2024 on the ESH 2024 Congress and the updated Guidelines. Video: https://medicaldigest.org/scientific-cont...
Haematology is at the forefront - interview with EHA President
11 Jun 2024
Contributed by Lukas
We asked Professor Antonio Almeida, the President of European Hematology Association about the benefits and perspectives in EHA as a European hematolo...
Obesity induced hypertension - report from ESH2024
10 Jun 2024
Contributed by Lukas
Professor Vasilios Kotsis on obesity induced hypertension and its state of the art treatment. Video: https://medicaldigest.org/scientific-contents/int...
Effect of renal denervation on blood pressure in patients with chronic kidney disease and uncontrolled hypertension - report from ESH2024
10 Jun 2024
Contributed by Lukas
Professor Roland Schmieder on the results of a prospective randomized sham-controlled study and explains the effects of renal denervation on blood pre...
Hypertension and beta-blocker choice: influence of age, stress, and co-morbidities - report from ESH2024
10 Jun 2024
Contributed by Lukas
Professor Sverre Erik Kjeldsen at the recent annual meeting of the European Society of Hypertension, held a lecture on the role of beta-blockers in th...
Overcoming the resistance - Is renal denervation the solution? - report from ESH2024
10 Jun 2024
Contributed by Lukas
Professor Konstantinos Tsioufis shares his thoughts on the novelties of kidney protection in hypertension. Video: https://medicaldigest.org/scientifi...
One heart and two kidneys: Promoting organ protection using SGLT-2 inhibitors in patients with hypertension - report from ESH2024
10 Jun 2024
Contributed by Lukas
Professor Francesca Mallamaci co-chaired a session at the current Annual Congress of the European Society of Hypertension on cardiovascular protective...
Why is it so difficult to reach the expected BP target in real-life patients? - report from ESH2024
06 Jun 2024
Contributed by Lukas
Professor Krzysztof Narkiewicz on why is it so difficult to reach the expected BP target in real-life patients. Video: https://medicaldigest.org/scien...
Time to act to improve adherence in hypertension management: bridging the gap between knowledge and action - report from ESH2024
06 Jun 2024
Contributed by Lukas
Professor Bryan Williams chaired an interesting symposium at ESH 2024. The joint ESH/ESC guideline on the diagnosis and treatment of hypertension and ...
Real-life hypertensive patients: Towards a holistic approach in clinical practice - report from ESH2024
05 Jun 2024
Contributed by Lukas
Professor Claudio Borghi chaired a symposium at ESH 2024 on two very important patient groups, diabetic patients and coronary patients, on antihyperte...
Hypertension and CAD: need of more SPCs - report from ESH2024
05 Jun 2024
Contributed by Lukas
Professor Sofie Brouwers explained at ESH 2024 that antihypertensive treatment for chronic coronary artery disease should be based on an ACE inhibitor...
Challenges in hypertension adherence to treatment - report from ESH2024
05 Jun 2024
Contributed by Lukas
Professor Michel Burnier shared his thoughts on why is adherence is a key factor in good hypertensive management at ESH 2024. Video: https://medicaldi...
HPV-associated head and neck cancers - report from Danube Symposium
15 May 2024
Contributed by Lukas
Professor Thomas Hoffmann, Director of the Department of Otolaryngology and Head and Neck Surgery at the University of Ulm, raises awareness of the gr...
Breakthroughs and challenges in the treatment of head and neck cancer - report from Danube Symposium
15 May 2024
Contributed by Lukas
Dr. Robert Sifrer, Director of the Department of Otolaryngology and Head and Neck Surgery at the University of Ljubljana, believes that the most impor...
Featured Clinical Researches: acute coronary syndromes, atrial fibrillation related ablation procedures and aortic valve replacements - report from ACC2024
19 Apr 2024
Contributed by Lukas
Professor George D. Dangas chaired the Featured Clinical Research on Monday and shared his insights on the trials about acute coronary syndromes, atri...
Late-Breaking Clinical Trials on Cholesterol Management, Hypertension and Exercise - report from ACC2024
19 Apr 2024
Contributed by Lukas
Professor Andrew M. Kates shared his insights on Late-Breaking Clinical Trials II, presented during at ACC.24: - Zilebesiran In Combination With A Sta...
Late Breaking Clinical Trial on ACC - report from ACC2024
19 Apr 2024
Contributed by Lukas
Professor Athena Poppas shared his insights on the Late Breaking Clinical Trial sessions: - Effect Of Edetate Disodium Based Chelation Infusions On Ca...
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF and STEP-HFpEF DM randomised trials - report from ACC2024
18 Apr 2024
Contributed by Lukas
Professor Mikhail Kosiborod shared his insights onthe STEP-HFpEF and STEP-HFpEF DM randomised trials. Discussed studies: - Semaglutide versus placebo...
Late-Breaking Clinical Trials V - report from ACC2024
17 Apr 2024
Contributed by Lukas
ACC Immediate-Past President Edward T. A. Fry chaired the Late Breaking Clinical Trial V. and shared his insights on the trials: - Coronary Sinus Redu...
Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials IV - report from ACC2024
17 Apr 2024
Contributed by Lukas
Professor Kathryn L. Berlacher shared his insights on Late-Breaking Clinical Trials IV, presented during at ACC.24: - Outcomes After Technology Assist...
Late Breaking Clinical Trial on interventional cardiology - report from ACC2024
17 Apr 2024
Contributed by Lukas
Professor Douglas E. Drachman shared his insights on the Late Breaking Clinical Trial sessions about interventional cardiology trials which he co-mo...
Lerodalcibep reduces LDL cholesterol by over 50% in high-risk patients - report from ACC2024
16 Apr 2024
Contributed by Lukas
Professor Eric Quinton Klug shared his insights on the LIBerate-HR trial. Among patients at high or very high risk for a heart attack or stroke, the a...
PROACT: Do ACE Inhibitors Help Prevent Cardiotoxicity in Patients Treated For Breast Cancer or Lymphoma? - report from ACC2024
16 Apr 2024
Contributed by Lukas
David Austin, the study's lead author shared his insights on the PROACT trial. Patients who took the ACE inhibitor enalapril while undergoing canc...
ULTIMATE-DAPT: Most Patients With ACS Can Safely Stop Aspirin One Month Post PCI - report from ACC2024
12 Apr 2024
Contributed by Lukas
Professor Gregg W. Stone shared his insights on the ULTIMATE-DAPT study. Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT...
EMPACT-MI: Empagliflozin Post MI Does Not Lower Risk of First HF Hospitalization, Death - report from ACC2024
12 Apr 2024
Contributed by Lukas
Professor Javed Butler shared his insights on the EMPACT-MI study. The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization...
Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial - report from ACC2024
12 Apr 2024
Contributed by Lukas
Professor Steven E. Nissen shared his insights on the TACTiC study, presented during a Late-Breaking Clinical Trial session at ACC.24. The study prove...
Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials - report from ACC2024
11 Apr 2024
Contributed by Lukas
ACC President B. Hadley Wilson shared his insights on Late-Breaking Clinical Trials I, presented during at ACC.24: - RELIEVE-HF: Does Impact of Inter...
Percutaneous Transvalvular Micro-axial Flow Pump in Infarct Related Cardiogenic Shock - report from ACC2024
11 Apr 2024
Contributed by Lukas
Professor Robert Roswell shared his insights on the DanGer Shock trial. Implantation of the Impella CP micro-axial flow pump in the hours after a hear...
Study Links E-Cigarette Use with Higher Risk of Heart Failure - report from ACC2024
11 Apr 2024
Contributed by Lukas
Dr. Yakubu Bene-Alhasan shared his insights on the large study that adds to growing body of evidence that vaping may harm the heart. People who use e-...
Overall Survival Results of KEYNOTE-564
05 Apr 2024
Contributed by Lukas
We asked Professor Stefan N. Symeonides, one of the authors of the KEYNOTE-564 study, about the trial and the new data presented on overall survival a...
Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
12 Feb 2024
Contributed by Lukas
We asked Professor David F. McDermott, investigator of the KEYNOTE-564 study, about the trial and the new data presented on overall survival at ASCO G...
Follicular Lymphoma highlights of the ASH 2023 Congress
26 Jan 2024
Contributed by Lukas
Professor Carla Casulo summarizes the most important highlights in the field of Follicular Lymphoma treatment after the 65th American Society of Hemat...
Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia - report from ASH2023
21 Dec 2023
Contributed by Lukas
Professor on frontline treatment with targeted agents in patients with Chronic Lymphocytic Leukemia. Video: https://medicaldigest.org/scientific-conte...
Real-World Outcomes With Brexucabtagene Autoleucel - report from ASH2023
21 Dec 2023
Contributed by Lukas
Professor Swetha Kambhampati on Mantle Cell Lymphoma: Real-World Outcomes With Brexucabtagene Autoleucel. Video: https://medicaldigest.org/scientific-...
Ibrutinib-Venetoclax Combination Found Effective Against Mantle Cell Lymphoma - report from ASH2023
21 Dec 2023
Contributed by Lukas
Professor Michael Wang explains their findings that combining ibrutinib and venetoclax improves progression-free survival and remission rates in patie...
Present and future of Multiple Myeloma management - report from ASH2023
21 Dec 2023
Contributed by Lukas
Professor Xavier Leleu explains the present and future of Multiple Myeloma management, how new regiments, new treatments will change how we treat pati...
Highlights of the ASH 2023 Congress
21 Dec 2023
Contributed by Lukas
Professor Mikkael Sekeres summarizes the most important highlights that presented at the 65th American Society of Hematology Annual Meeting. Video: ht...
Chronic Myeloid Leukemia: Novel Therapeutic Approaches - report from ASH2023
20 Dec 2023
Contributed by Lukas
Professor Carmen Fava summarizes the therapeutic novelties of Chronic Myeloid Leukemia management at the 65th American Society of Hematology Annual Me...
Acute myeloid leukemia highlights of ASH 2023 Congress
20 Dec 2023
Contributed by Lukas
Professor Eunice S. Wang summarizes the most important highlights in the field of Acute Myeloid Leukemia treatment at the 65th American Society of Hem...
Chronic Myeloid Leukemia highlights of ASH 2023 Congress
20 Dec 2023
Contributed by Lukas
Professor Giuseppe Saglio summarizes the most important highlights in the field of Chronic Myeloid Leukemia treatment at the 65th American Society of ...
Multiple Myeloma highlights of ASH 2023 Congress
20 Dec 2023
Contributed by Lukas
Professor Andrzej Jakubowiak summarizes the most important highlights in the field of MultiplMyeloma treatment at the 65th American Society of Hematol...
Dramatically Worse Myeloma Outcomes in Real World vs. Trials - report from ASH2023
20 Dec 2023
Contributed by Lukas
Dr. Alissa Visram on the presented the data during 65th American Society of Hematology Annual Meeting. Patients with multiple myeloma who were treated...
State of the art ALL treatement in 2023 - report from ASH2023
19 Dec 2023
Contributed by Lukas
Professor Marlise R. Luskin summarizes the state of the art acute lymphoblastic leukemia treatement at the 65th American Society of Hematology Annual ...
Acute myeloid leukemia highlights of the ASH 2023 Congress
19 Dec 2023
Contributed by Lukas
Professor Agnieszka Wierzbowska summarizes the most important highlights in the field of acute myeloid leukemia treatment at the 65th American Society...
Diagnostic and Therapeutic Novelties of Multiple Myeloma Management at ASH2023
19 Dec 2023
Contributed by Lukas
Professor Enrique Ocio summarizes the diagnostic and therapeutic novelties of Multiple Myeloma management at the 65th American Society of Hematology A...
Non-Hodgkin Lymphoma highlights of the ASH 2023 Congress - report from ASH2023
19 Dec 2023
Contributed by Lukas
Professor Umberto Vitolo summarizes the most important highlights in the field of Non-Hodgkin Lymphoma treatment at the 65th American Society of Hemat...
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone Outperforms VRd Alone for Multiple Myeloma - report from ASH2023
18 Dec 2023
Contributed by Lukas
Professor Pieter Sonneveld explains that newly diagnosed patients with multiple myeloma who received daratumumab along with the standard care regimen ...
Revumenib Found Effective Against High-Risk KMT2Ar Acute Leukemia - report from ASH2023
18 Dec 2023
Contributed by Lukas
Professor Ibrahim Aldoss explains that patients with relapsed or refractory acute leukemia with rearrangement in the lysine methyltransferase 2a gene,...
Auto-HCT Improves PFS, Relapse Rates in Relapsed LBCL Subset During Complete Response - report from ASH2023
15 Dec 2023
Contributed by Lukas
Professor Mazyar Shadman on the findings from a real-world, retrospective study that were presented during the 2023 ASH Annual Meeting: Autologous hem...
Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL - report from ASH2023
15 Dec 2023
Contributed by Lukas
Professor Peter Hillmen on the combination of ibrutinib and venetoclax, at a duration determined by minimal residual disease, improved progression-fre...
Interpretable Artificial Intelligence Differentiates Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia - report from ASH2023
13 Dec 2023
Contributed by Lukas
Professor Andrew Srisuwananukorn's research revealed that an AI-powered machine learning algorithm, when examining digital whole-slide images of d...
CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases - report from ASH2023
13 Dec 2023
Contributed by Lukas
Professor Fabien Mueller explains preliminary results from an early-stage study presented at the American Society of Hematology meeting over the weeke...
Medical Treatment of Renal Cell Carcinoma in 2023
04 Dec 2023
Contributed by Lukas
Professor Viktor Grünwald at ESMO 2023 had a lecture on prognostic factors of renal cell carcinoma and in a recent podcast analyzed the importance of...
Lung Cancer highlights of ESMO 2023 Congress
29 Nov 2023
Contributed by Lukas
Professor Luis Paz-Ares explains the most important novelties in the field of lung cancer treatement after ESMO 2023. - Early stage trails: ADAURA, AL...
State of art lipid-lowering treatment in 2023
23 Nov 2023
Contributed by Lukas
Professor Stephen Nicholls summarizes the state of art lipid lowering therapy after ESC 2023. Video: https://medicaldigest.org/scientific-contents/int...
The importance of intensive lipid lowering in CV risk reduction: the role of early combination treatment
23 Nov 2023
Contributed by Lukas
Professor Alberto Zambon explains the significance of intensive lipid lowering therapy in cardiovascular risk reduction after ESC 2023. He highlights ...
Lung cancer highlights of the ESMO 2023 Congress
10 Nov 2023
Contributed by Lukas
Professor Benjamin Besse shares his insight on novelties in lung cancer treatment presented at ESMO 2023 Congress. Topics mentioned are targeted thera...
Melanoma highlights of ESMO 2023 Congress
08 Nov 2023
Contributed by Lukas
Professor Karijn Suijkerbuijk shares with us some highlights from ESMO 2023 on Melanoma. On neoadjuvant treatments of cutaneous melanoma, a small but ...
RCC highlights of ESMO 2023 Congress
08 Nov 2023
Contributed by Lukas
Camillo Porta shares his thoughts about the most important novelties in RCC treatment. Studies such as: - Belzutifan/LITESPARK studies: LITESPARK-003 ...
Genitourinary cancer highlights of ESMO 2023 Congress
08 Nov 2023
Contributed by Lukas
Silke Gillessen explains the most important stories in GU cancers at ESMO 2023. Studies such as: - EV-302/KEYNOTE-A39 trial: Risk of death was reduced...
Breast Cancer highlights of the ESMO 2023 Congress
07 Nov 2023
Contributed by Lukas
Professor Hope Rugo shares her insights on the breast cancer highlights of #ESMO23 meeting, and also how they apply them in clinical practice. This wa...
Treatment of mRCC in real world settings - report from ESMO2023
06 Nov 2023
Contributed by Lukas
Professor Daniel Heng shares his thoughts on the developments of the last few years in the field of mRCC. Video: https://medicaldigest.org/scientific-...
Antibody-Drug Conjugate Boosts Survival in Recurrent/Metastatic Cervical Cancer - report from ESMO2023
06 Nov 2023
Contributed by Lukas
Professor Krishnansu Sujata Tewari explains the results from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with tisotumab v...
Data Shows Survival Benefits with Tisotumab Vedotin in Cervical Cancer - report from ESMO2023
03 Nov 2023
Contributed by Lukas
Professor Ignace B. Vergote explains the results from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with tisotumab vedotin ...
Late-breaking studies from ESMO 2023 - report from ESMO2023
03 Nov 2023
Contributed by Lukas
Professor Paweł Sobczuk shares his thoughts on five interesting studies presented during #ESMO23. These groundbreaking studies is form different tumo...
KEYNOTE-942 mRNA-Based vaccine and novel techniques in the field of melanoma - report from ESMO2023
03 Nov 2023
Contributed by Lukas
Professor Jeffrey Weber shares his thoughts on the novel techniques in the field of melanoma. Like 5-Year Efficacy and Biomarker Results from CheckMat...
Targeted Combination Wins in KRAS-Positive Metastatic Colorectal Cancer - report from ESMO2023
02 Nov 2023
Contributed by Lukas
Professor Filippo Pietrantonio discusses the influence of primary results from the phase 3 CodeBreak 300 trial of sotorasib plus panitumumab on KRAS G...
Better use of existing drugs increases cervical cancer survival and reduces recurrence - report from ESMO2023
02 Nov 2023
Contributed by Lukas
Professor Krishnansu Sujata Tewari explains the results from he INTERLACE phase 3 trial, assessed whether a short course of induction chemotherapy pri...
Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer - report from ESMO2023
02 Nov 2023
Contributed by Lukas
Professor Mary McCormack explains the results from the GCIG INTERLACE trial presented in a Presidential Symposium at the ESMO Congress 2023. Phase III...
The CodeBreak 300 Trial in KRAS G12C-mutated mCRC - report from ESMO2023
01 Nov 2023
Contributed by Lukas
Professor Clara Montagut Viladot discusses the primary results from the phase 3 CodeBreak 300 trial of sotorasib plus panitumumab in KRAS G12C–mutat...
Survival Improved With Nivolumab Plus Chemo in Urothelial Carcinoma - report from ESMO2023
01 Nov 2023
Contributed by Lukas
Professor Michiel van der Heijden presented the results of CheckMate 901, a phase III trial evaluating the combination of nivolumab plus gemcitabine/c...
Amivantamab Plus Chemotherapy as New First-Line Standard of Care in EGFR Exon 20 Insertion-Mutated Advanced NSCLC - report from ESMO2023
01 Nov 2023
Contributed by Lukas
Professor Nicolas Girard explains primary efficacy results from the phase 3 PAPILLON trial of amivantamab plus chemotherapy in EGFR exon 20 insertion–...
Selpercatinib improves outcomes in RET-mutant medullary thyroid cancer - report from ESMO2023
31 Oct 2023
Contributed by Lukas
Professor Laura Locati highlights findings from phase 3 LIBRETTO-531 trial, that has demonstrated the superiority of selpercatinib, a highly selective...